Analyst firms · Citigroup · TECH
Citigroup TECH price target and rating history
Bio-Techne Corp (TECH) · Health Care
Citigroup rates Bio-Techne Corp (TECH) Buy with a $70 price target, as of its latest action on Aug 21, 2025. It has published 3 rating actions on TECH since December 2022, including 2 upgrades and 1 downgrade. Across 3 firms with a TECH price target in the last 12 months, the median target is $65.
- Current rating
- Buy
- Price target
- $70
- Median target, all firms
- $65
- Actions on TECH
- 3
Citigroup price target on TECH
Every Citigroup rating on TECH
- Aug 21, 2025
- May 22, 2024
- Dec 12, 2022
How other firms rate TECH
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wells Fargo | Equal Weight | $73 | Aug 13, 2026 |
| Piper Sandler | Neutral | $65 | Jun 11, 2026 |
| RBC Capital Markets | Outperform | $62 | May 15, 2026 |
Questions about Citigroup and TECH
- What is Citigroup's price target for TECH?
- Citigroup's latest stated price target for Bio-Techne Corp (TECH) is $70, from its action on Aug 21, 2025.
- What is Citigroup's rating on TECH?
- Citigroup rates TECH Buy, a bullish rating, as of Aug 21, 2025.
- When did Citigroup last change its view on TECH?
- On Aug 21, 2025, Citigroup upgrades to Buy from Neutral, price target $70.
- How does Citigroup's TECH target compare with other analysts?
- Across 3 firms with a TECH price target in the last 12 months, the median target is $65.
More TECH rating histories
All Citigroup ratingsTECH news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.